Asian Biomedicine最新文献

{"title":"A comprehensive analysis of the incidence of chromosomal abnormalities in hematologic malignancies post-COVID-19 outbreak in King Chulalongkorn Memorial Hospital, Thailand.","authors":"Montakarn Tansatit, Nutcharee Jongpornchai, Suwannee Songchart, Kittipornpan Krajokpap, Hudadini Da-Oh","doi":"10.2478/abm-2026-0022","DOIUrl":"10.2478/abm-2026-0022","url":null,"abstract":"<p><strong>Background: </strong>Hematologic malignancies, including leukemia, lymphoma, and bone marrow disorders, are complex cancers often associated with chromosomal abnormalities. The emergence of COVID-19 raised concerns about its potential to induce genomic instability, influencing the prevalence and cytogenetics of these malignancies.</p><p><strong>Objectives: </strong>This study evaluates whether the COVID-19 pandemic affected the incidence, demographics, or chromosomal abnormalities in hematologic malignancies at King Chulalongkorn Memorial Hospital, Thailand, between 2018 and 2024.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 3,077 bone marrow samples processed for cytogenetic evaluation. Samples were categorized into pre-COVID-19 (2018-2019) and post-COVID-19 (2020-2024) periods. Trends in disease incidence, patient demographics, and chromosomal abnormalities were analyzed statistically.</p><p><strong>Results: </strong>The overall incidence rates of hematologic malignancies, including leukemia, lymphoma, and bone marrow disorders, remained stable throughout the study. Male-to-female ratios and average ages of onset showed no significant changes. Except for a transient rise in chromosomal abnormalities in chronic lymphocytic leukemia during 2023, no new or recurring abnormalities were identified. The mean age of onset for various malignancy categories remained consistent across the study period, and the pandemic did not significantly alter hematologic cancer trends.</p><p><strong>Conclusions: </strong>The findings indicate that the COVID-19 pandemic did not substantially affect the incidence, cytogenetics, or demographics of hematologic malignancies. These results provide reassurance about the resilience of diagnostic and monitoring systems during the pandemic. Further studies are recommended to explore potential long-term implications of COVID-19 on hematologic malignancies.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 3","pages":"194-201"},"PeriodicalIF":1.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13427362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148652915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of lactoferrin and progesterone on the endometriotic lesion in a female rat model.","authors":"İrem Şenyuva, Duygu Baki Acar, Hasan Hüseyin Demirel Bayat, Funda Karabağ, Ece Tunç","doi":"10.2478/abm-2026-0019","DOIUrl":"10.2478/abm-2026-0019","url":null,"abstract":"<p><strong>Background: </strong>Lactoferrin (LF), a multifunctional glycoprotein of the transferrin family, exhibits anti-inflammatory and immunomodulatory properties. Endometriosis is an estrogen-dependent chronic inflammatory disease commonly treated with progesterone therapy; however, progesterone receptor (PGR) resistance in endometriotic lesions has increased interest in immunomodulatory approaches.</p><p><strong>Objective: </strong>To evaluate the effects of LF alone and combined with progesterone on endometriotic lesions in a rat model.</p><p><strong>Methods: </strong>An endometriosis model was induced in female Wistar Albino rats. Rats with confirmed endometriotic lesions were randomly divided into 4 equal groups and received the following oral treatments: Control (0.5% carboxymethylcellulose), bovine LF (bLF) (100 mg/kg/d), progesterone (0.3 mg/kg/day), combination therapy (bLF [100 mg/kg/d] + progesterone [0.3 mg/kg/d]). After treatment, the rats were euthanized, histopathological and biochemically anayses were done.</p><p><strong>Results: </strong>No statistically significant differences were observed in volume and adhesion scores of endometriotic lesions before and after treatment (<i>P</i> = 0.653, <i>P</i> = 0.413, <i>P</i> = 0.890, respectively). However, PGR and inflammatory cytocine levels were decreased in all treatment groups (<i>P</i> = 0.001). Although serum progesterone levels did not differ between groups (<i>P</i> = 0.06), serum LF levels were lower in the progesterone-only group (<i>P</i> = 0.001). Total antioxidant status (TAS) and Plasma total oxidant status (TOS) showed no significant differences among groups (<i>P</i> = 0.623 and <i>P</i> = 0.318, respectively).</p><p><strong>Conclusion: </strong>LF, alone or combined with progesterone, reduced inflammatory cytokine levels associated with endometriosis-related pain, suggesting potential therapeutic value. Further studies are needed to clarify its role in progesterone resistance and the clinical management of endometriosis.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 3","pages":"161-169"},"PeriodicalIF":1.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13427365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148652891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-tuberculosis drug-induced hepatotoxicity in people living with HIV.","authors":"","doi":"10.2478/abm-2026-0016","DOIUrl":"10.2478/abm-2026-0016","url":null,"abstract":"","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 3","pages":"147-148"},"PeriodicalIF":1.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13427360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148652840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, risk factors, and outcomes of anti-tuberculosis drug-induced hepatotoxicity in people with and without HIV in Thailand and the Philippines.","authors":"Ryan Christopher Geturbos Atuel, Emmanuel A Gutierrez, Napon Hiranburana, Tanakorn Apornpong, Sasiwimol Ubolyam, Ma Tarcela S Gler, Anchalee Avihingsanon, Sivaporn Gatechompol, Stephen J Kerr","doi":"10.2478/abm-2026-0020","DOIUrl":"10.2478/abm-2026-0020","url":null,"abstract":"<p><strong>Background: </strong>Anti-tuberculosis drug-induced hepatotoxicity (DIH) is a common complication among people living with HIV (PLWH), potentially leading to treatment interruptions.</p><p><strong>Objective: </strong>To determine the incidence of DIH and identify risk factors in Thai and Filipino PLWH on tuberculosis (TB) treatment, compared with those with TB mono-infection.</p><p><strong>Methods: </strong>We conducted a cohort study of Thai and Filipino adults with active TB using retrospective data from Thailand (2000-2024) and prospective data from the Philippines (2024). DIH was defined as AST or ALT ≥3 times the upper limit of normal. Logistic regression was used to assess DIH risk factors among PLWH; TB treatment outcomes were compared by DIH status.</p><p><strong>Results: </strong>Among 222 participants (138 PLWH, 84 HIV-negative), median age was 38 years, 63% were male, and median body mass index (BMI) was 18.2 kg/m². DIH occurred in 13.8% of PLWH and 9.5% of HIV-negative individuals (<i>P</i> = 0.35), with median onset at 10 and 3 weeks, respectively. Among PLWH, hepatitis C co-infection (aOR 5.84, 95% CI 1.51-22.55, <i>P</i> = 0.01) and lower BMI (aOR 0.78/kg/m², 95% CI 0.63-0.97, <i>P</i> = 0.03) were independently associated with DIH. Dolutegravir use showed a non-significantly lower DIH risk (OR 0.51, 95%CI, 0.18 - 1.42). TB treatment success was similar between those with and without DIH (92.6% vs 90.3%); mortality was slightly higher with DIH (3.7% vs 1.5%).</p><p><strong>Conclusions: </strong>Hepatitis C co-infection and low BMI are key risk factors for DIH among PLWH receiving TB treatment. Despite these risks, DIH did not significantly impact treatment outcomes.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 3","pages":"170-181"},"PeriodicalIF":1.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13427366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148652832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy and pharmacokinetic study of antituberculosis treatment in patients with end-stage renal disease undergoing hemodialysis.","authors":"Wei Song, Zhao Yang, Yuqian Zhao, Bing Liu, Musong Li, Wei Du, Ning Niu, Jianru Jia","doi":"10.2478/abm-2026-0021","DOIUrl":"10.2478/abm-2026-0021","url":null,"abstract":"<p><strong>Background: </strong>Patients with end-stage renal disease (ESRD) undergoing hemodialysis exhibit a 10-25 times greater risk of tuberculosis (TB), underscoring the urgent need for optimized treatment strategies to improve prognosis.</p><p><strong>Objective: </strong>The present study evaluates the efficacy and pharmacokinetics of personalized anti-TB dosing in hemodialysis patients with ESRD and TB, to guide treatment optimization.</p><p><strong>Methods: </strong>This retrospective study included 90 hemodialysis patients with ESRD and TB (2020 - 2024). The control group (n = 45) received conventional anti-TB dosing; the study group (n = 45) received individualized dosing/timing. All received HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol) and high-flux hemodialysis or hemodiafiltration. Efficacy endpoints included sputum conversion (4, 8, and 12 weeks), imaging at 12 weeks, and clinical effectiveness. Blood samples were collected before/during/after/dialysis intervals to calculate C_max, C_min, AUC_0-24, CL, CLDAA, ER, t^½, and adverse reactions.</p><p><strong>Result: </strong>No significant baseline differences existed between groups (<i>P</i> > 0.05). The study group showed higher sputum conversion rates, 12-week radiographic improvement, and overall effectiveness (<i>P</i> < 0.05). Pharmacokinetic (PK) analysis revealed elevated C_max, C_min, AUC_0-24 for all anti-TB drugs (<i>P</i> < 0.05). Rifampicin clearance was unchanged (<i>P</i> > 0.05), while others decreased (<i>P</i> < 0.05). Half-life shortened on dialysis days (<i>P</i> < 0.01). Adverse reactions were markedly reduced in the study group (<i>P</i> < 0.01).</p><p><strong>Conclusions: </strong>For hemodialysis patients with ESRD and TB, tailoring anti-TB drug regimens based on PK profiles can enhance efficacy and minimize adverse effects, offering a safe and personalized treatment pathway.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 3","pages":"182-193"},"PeriodicalIF":1.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13427363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148652854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the gap: optimizing conduction system pacing for cost-effectiveness and widespread adoption in low-resource settings.","authors":"Ronpichai Chokesuwattanaskul, David Hayes","doi":"10.2478/abm-2026-0018","DOIUrl":"10.2478/abm-2026-0018","url":null,"abstract":"<p><strong>Background: </strong>Right ventricular apical (RVA) pacing often leads to interventricular dyssynchrony and pacing-induced cardiomyopathy. Conduction system pacing (CSP), particularly Left Bundle Branch Area Pacing, provides a physiologic alternative. In Limited Resource Countries (LRCs) like Thailand, Cardiac Resynchronization Therapy (CRT) under-penetration persists due to high costs and a shortage of operators skilled in coronary venous anatomy.</p><p><strong>Objective: </strong>To share the experience and provide clinical update of CSP as a sustainable, cost-effective physiological pacing strategy to improve access to advanced arrhythmia management in resource-constrained environments.</p><p><strong>Methods: </strong>This review explores the implementation of minimalist protocols and CSP-based CRT. Scalability strategies include specialized training programs, device reprocessing, and the establishment of regional longitudinal registries to bridge infrastructure gaps.</p><p><strong>Results: </strong>CSP-based CRT can reduce device costs by nearly 50% compared with traditional triple-lead systems. This modality effectively mitigates the hemodynamic risks of RVA pacing while bypassing the technical and financial barriers of conventional CRT.</p><p><strong>Discussion: </strong>Despite its advantages, CSP adoption requires overcoming infrastructure challenges, specifically the lack of automated remote monitoring. Optimizing clinical outcomes in LRCs necessitates standardized training, robust data collection, and innovative resource management to ensure equitable access to life-saving technology.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 3","pages":"155-160"},"PeriodicalIF":1.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13427361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148652820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare subgroup of A phenotype-a case series.","authors":"Nur Ilyia Syazwani Saidin, Nurul Anis Che Anuar, Mohd Nazri Hassan, Noor Haslina Mohd Noor, Zefarina Zulkafli, Hisham Atan Edinur","doi":"10.2478/abm-2026-0023","DOIUrl":"10.2478/abm-2026-0023","url":null,"abstract":"<p><p>Testing for ABO incompatibility between a potential blood donor and recipient is the cornerstone of pretransfusion testing. Occasionally, weak agglutination reactions occur due to low expression of A and B antigens on the surface of red blood cells. This can lead to inconsistencies in blood group typing, as seen in a case where a patient's forward and reverse typing showed discrepancies. Following a comprehensive analytical assessment, the patient was identified as having a distinctive variant of blood group A, belonging to the less common subgroups-A₃, A_end, A_x, A_m, A_y, and A_el. Herein, we present 3 case series of ABO subgroups identified through extended ABO blood grouping procedures.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 3","pages":"202-205"},"PeriodicalIF":1.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13427364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148652862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut-testis axis: how microbiota influence male reproductive health.","authors":"Ruiyang Hu, Jingxing Wu, Nianben Chen, Wenjun Ma, Qinglin Hu","doi":"10.2478/abm-2026-0017","DOIUrl":"10.2478/abm-2026-0017","url":null,"abstract":"<p><p>The intestinal flora forms a complex ecosystem that interacts with the host, influencing health and fitness through mechanisms that connect with distant organs like the brain, liver, muscles, and testes. The gut microbiota plays a vital role in regulating androgen production and metabolism, and can cross the blood-testis barrier to influence spermatogenesis. This review highlights the significance of the gut-testis axis in male reproductive and sexual health, based on extensive studies exploring how gut microbes impact testicular function. Gaining this understanding deepens our knowledge of the gut-testis axis and its role in male reproductive health.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 3","pages":"149-154"},"PeriodicalIF":1.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13435932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of economic burden of overweight and obesity and their associated factors in Saudi Arabia.","authors":"Mubashir Zafar, Abdullah Ali Albrahimi, Naif Mohammed Salem Alanezi","doi":"10.2478/abm-2026-0013","DOIUrl":"10.2478/abm-2026-0013","url":null,"abstract":"<p><strong>Background: </strong>Overweight and obesity represent significant public health challenges in Saudi Arabia with substantial economic implications.</p><p><strong>Objective: </strong>To estimate the economic burden of overweight and obesity in Saudi Arabia and identify associated factors.</p><p><strong>Methods: </strong>This cross-sectional study utilized a mixed-methods approach combining primary survey data with secondary national health data. A total of 667 participants were recruited through stratified random sampling using a validated structured questionnaire. Direct medical costs were estimated using healthcare utilization data, while indirect costs were calculated using the human capital approach. Logistic regression analysis identified factors associated with high economic burden. Statistical significance was set at <i>P</i> < 0.05.</p><p><strong>Results: </strong>The total annual economic burden of overweight and obesity in Saudi Arabia was estimated at SAR 7.6 billion (US$2.0 billion), representing 1.2% of GDP. Direct medical costs accounted for SAR 5.2 billion, while indirect costs totaled SAR 2.4 billion. Among participants, 46.8% experienced a high individual economic burden. Younger age (18-30 years) was significantly associated with higher economic burden compared to older adults (adjusted odds ratio [AOR] = 2.9, 95% confidence interval [CI]: 2.2-4.0, <i>P</i> = 0.004). Primary education level was associated with higher economic burden compared to university education (AOR = 3.9, 95% CI: 2.0-9.2, <i>P</i> = 0.045). Body mass index (BMI) ≥ 30 kg/m² was associated with higher economic burden (AOR= 3.0, 95% CI: 2.2-3.7, <i>P</i> = 0.001).</p><p><strong>Conclusion: </strong>The economic burden of overweight and obesity in Saudi Arabia is substantial and disproportionately affects younger adults, individuals with lower education, and those with higher BMI. These findings support targeted interventions and policy initiatives aligned with Saudi Vision 2030 healthcare transformation goals.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 2","pages":"123-129"},"PeriodicalIF":1.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148263009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of maternal anemia on neonatal neurodevelopment: a systematic review and meta-analysis.","authors":"Fengying He, Chiqiong Liu","doi":"10.2478/abm-2026-0010","DOIUrl":"10.2478/abm-2026-0010","url":null,"abstract":"<p><strong>Background: </strong>Maternal anemia, particularly iron deficiency anemia (IDA), is a significant global health concern, affecting approximately 30% of women worldwide. Iron plays a crucial role in fetal brain development, influencing processes such as myelination, neurotransmitter synthesis, and oxygen transport. Despite theoretical links between prenatal iron deficiency (ID) and neurodevelopment, its actual effects on neonatal cognitive, motor, and socioemotional outcomes remain unclear. This study systematically evaluates the impact of maternal anemia on neonatal neurodevelopment.</p><p><strong>Methods: </strong>A systematic literature review was conducted using PubMed, Scopus, and Web of Science, covering studies published until December 2024. Keywords related to prenatal ID, maternal anemia, and neonatal neurodevelopment were used. Eligible studies focused on maternal iron levels and neonatal outcomes, excluding animal studies, non-English publications, and reviews. Out of 1,388 screened articles, 6 studies were selected for meta-analysis. Data were synthesized using standardized methods, and pooled effect sizes were calculated. Study quality was assessed using the Newcastle-Ottawa Scale.</p><p><strong>Results: </strong>The meta-analysis included 6 studies, with sample sizes ranging from 178 to 636 participants. Neonatal outcomes were assessed using the Neonatal Behavioral Assessment Scale (NBAS), Bayley Scales of Infant Development, and Mullen Scales of Early Learning. No significant correlation was found between maternal anemia and neonatal outcomes, including habituation (<i>P</i> = 0.93), orientation (<i>P</i> = 0.76), state regulation (<i>P</i> = 0.90), motor maturity (<i>P</i> = 0.71), autonomic stability (<i>P</i> = 0.10), early learning composite (<i>P</i> = 0.65), and gross motor skills (<i>P</i> = 0.59). Heterogeneity was low to moderate, and no significant publication bias was detected. Variability in iron supplementation did not yield consistent benefits.</p><p><strong>Conclusion: </strong>Maternal anemia does not significantly impact early neonatal neurodevelopment. While additional studies are unlikely to reveal meaningful effects during the neonatal period, the potential for delayed or long-term neurodevelopmental impacts remains uncertain and warrants further longitudinal research.</p>","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"20 2","pages":"85-95"},"PeriodicalIF":1.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148262938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}